inflammatory potential of CD38 positive memory T lymphocytes after stimulation and performed single-cell RNA sequencing analyses.

**Results:** CD38 Expression is increased on certain immune cell subsets: Plasmablasts and unswitched Memory B cells, as well as plasmacytoid dendritic cells and CD16+ non-classical monocytes. We observed a drastic increase CD38 in both memory CD4 and CD8 T lymphocytes in SLE patients. These cells were mostly effector T cells (and not regulatory T cells) and expressed other markers of T cell activation and proliferation. We found an enrichment of CD38+ memory T cells in the urine of patients with lupus nephritis. After polyclonal stimulation of T cells, CD38+ produced less inflammatory cytokines. Preliminary single-cell sequencing results indicate that CD38+ T-lymphocytes have decreased clonal diversity and that these cells express genes associated with exhaustion and type 1 interferon response.

**Conclusion:** Increased CD38 expression on various lymphocyte subsets provides an additional rationale for investigating CD38-directed therapies in SLE. Increased CD38 expression has been reported in other autoimmune diseases and is involved in the regulation of Tfh and B cells. Therefore, targeting CD38 could not only deplete plasma cells but also has the potential to target interferon alpha producing plasmacytoid dendritic cells and modulate inflammatory T cell functions.

**Disclosure of Interests:** Lennard Ostendorf; None declared, Philipp Enghard; None declared, Pawelzurek; None declared, Frederik Heinrich; None declared, Mir-Farzin Masrhourghi; None declared, Gerd Rüdiger Burmeister Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Andreas Radbruch; None declared, Falk Heipe; None declared, Tobias Alexander; None declared

**DOI:** 10.1136/annrheumdis-2020-eular.6531

**T FOLLICULAR HELPER CELLS MAY BE INVOLVED IN THE LUPUS DEVELOPMENT IN HIGH FAT DIET-INDUCED OBESITY MICE**

R. Quinet1, X. Zhang2, J. Meng3, X. Shi4, H. Al5, N. Kumar6, L. Hellmers7, T. Washington8, W. Davis9, Z. Zakem10, Z. You11, Oschner Medical Center, Rheumatology, New Orleans, United States of America; 2Ochsner Medical Center, Institute of Translational Research, New Orleans, United States of America; 3Tulane University School of Medicine, Structure and Cell Biology, New Orleans, United States of America

**Background:** System lupus erythematosus (SLE) is an autoimmune disease that is associated with skin rash and multiple organs. It is known that obesity is a major factor contributing to the onset and progression of autoimmune diseases including SLE. Our previous study showed that circulating T follicular helper (Tfh) cells played an important role in autoimmune development in SLE patients. A recent study showed that Tfh cells promote B cell production of IgA antibodies, which help shape the composition of the gut microbiota and may modulate obesity.

**Objectives:** By establishing an obesity-associated lupus mouse model, we investigated the pathophysiological link of obesity, SLE and Tfh cells using MRL/lpr lupus prone mice.

**Methods:** Twenty MRL/lpr mice (10 male and 10 female) were randomized equally fed with a regular diet (RD) or high fat diet (HFD, 60% calories comprised of fat). Their body weights were recorded weekly as an indicator of obesity achievement. SLE progression was monitored weekly by development of skin lesion and urine protein levels assessed by Bradford assay. Blood was collected for IgG, anti-dsDNA and anti-nuclear antibody (ANA) detection. At the endpoint of week 14, spleen was measured and weighted. Spleen, kidney, and dorsal skin were collected and embedded for H&E, PAS, Masson's staining, and immune complex staining to detect active histopathological lupus lesions and be quantified as histological skin score and kidney index. Tfh cells in spleen were identified by immunohistochemistry (IHC) staining glomerulus of kidney.

**Results:** Obesity was achieved with a significant difference of mouse body weight between the RD and HFD groups by week 3 and continued until week 14 (p<0.05) to p<0.01). Evidence of SLE development, such as skin rash on the dorsal neck and back in HFD group showed up as earlier as week 6 and occurred in 55.6% of the HFD group vs 11.1% of the RD group (p<0.05), with a higher histological score of skin in HFD group (p<0.05). Proteinuria was increased from 11 to 14 week in male HFD group with an elevated kidney index and immune-complex deposits in their glomerulus of kidney. There was an increased trend of anti-dsDNA and IgG titer in HFD group, but no difference of ANA was observed between these two groups. Splenomegaly was observed in the HFD mice (p<0.05). The Tfh cells in the spleen of HFD group were higher than RD group.

**Conclusion:** Our results showed accelerated and greater severity of lupus development in MRL/lpr mice with HFD compared to mice on RD, indicating HFD-induced obesity exacerbates lupus development in mice. Tfh cells may be involved in the relation of obesity and SLE, with a potential to be used to investigate the mechanism underlying the link between obesity and SLE development. Interventions to reduce body weight or target Tfh cells may improve both lupus symptoms and outcomes in genetically predisposed SLE patients.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.6496

**AB0140**

**BAFF NEUTRALIZATION HAS JANUS-FACED EFFECT ON ATEROSCLEROSIS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

F. Saidoune1, N. Charles1, J. Chezel2, B. Escoubet2, T. Papo2, A. Niccolit3, K. Sacre1.

1Université Paris Diderot, Paris, France; 2Université Paris Diderot INSERM, Paris, France

**Background:** Cardiovascular diseases (CVD) are the leading cause of death in systemic lupus erythematosus (SLE). B cells play a key role in the pathogenesis of lupus and anti-BFf therapy has been approved in SLE. Since mature B cells also promote atherosclerosis, BAFF neutralization is expected to have an atheroprotective effect in SLE.

**Objectives:** The aim of our study was to test this hypothesis using a new mouse model with a mix susceptibility to lupus and atherosclerosis that received or not an anti-BAFF treatment, and in a cohort of SLE patients in whom we monitored carotid plaques, the B cell compartment and BAFF levels.

**Methods:** The effect of BAFF on atherosclerosis associated with lupus was investigated in the atherosclerosis- and lupus-prone ApoE-D2Z7K mouse model and in a cohort of SLE patients. Mice were treated with a blocking anti-BAFF monoclonal antibody (Ab), while fed with a standard chow diet. Carotid plaque and carotid intima media thickness were assessed by ultrasound at baseline and during follow-up in SLE patients asymptomatic for CVD.

**Results:** Anti-BAFF Ab in ApoE-D2Z7K mice induces a B cell depletion, it efficiently treated lupus, improved atherosclerosis lesions in mice that had low plasma cholesterol levels but worsened the lesions in mice with high cholesterol levels. In that case, the atheroprotective effect of the BAFF-BAFFR signaling inhibition on B cells was counterbalanced by the proatherogenic effect of the BAFF-TACI signaling inhibition on macrophages. In SLE patients, BAFF blood levels were associated with subclinical atherosclerosis. Anti-BAFF Ab treatment had a differential effect on the intima media thickness progression in SLE patients depending on the body mass index.

**Conclusion:** Depending on the balance between metabolic- and B cell-induced proatherogenic conditions, anti-BAFF could be respectively detrimental or beneficial on atherosclerosis development in SLE

**Acknowledgments:** Guillaume Even, Yasmine Lamri, Anh-Thu Gaston.

**Disclosure of Interests:** Fanny Saidoune Grant/research support from: supported by a research partnerships between the academic and GlaxoSmithKline France. Anti-BAFF mAb (IgG1, clone 10F4B6) in mice was provided by Glaxosmithkline. Nicolas Charles: None declared, Julie Chezel: None declared, Brigitte Escoubet: None declared, Thomas Papo: None declared, Antonino Nicoletti: None declared, Karim sacre: None declared

**DOI:** 10.1136/annrheumdis-2020-eular.988

**AB0141**

**MYCOPHENOLATE MOFETIL, INHIBITOR OF INOSINE-5'-MONOPHOSPHATE DEHYDOGENASE, REGULATES DIFFERENTIATION, MATURATION AND FUNCTION OF HUMAN DENDRITIC CELL SUBSETS**

M. Shigesaka1, T. Ito1, M. Inaba1, Y. Azuma1, S. Tsuchimoto1, Y. Son1, Y. Ozaki1, S. Nomura1, Y. O. Kansai Medical University, First Dept. Internal Medicine, Hirakata City, Osaka, Japan

**Background:** Systemic lupus erythematosus (SLE) is a heterogeneous disease in which excessive inflammation, autoantibodies, and complement...